NEW YORK (GenomeWeb) – Horizon Discovery today announced it will acquire Vienna-based cell engineering firm Haplogen Genomics.

The purchase is for an initial consideration of £6.0 million ($9.1 million) in cash and the issue of new ordinary shares with further potential earn-out payments based on future performance. The purchase consists of gross cash consideration of £3.0 million and the issue of new ordinary shares having an aggregate value of £3.0 million. The deal includes the potential for payments of stock worth up to £3.9 million based on future performance.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.